• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email
    SC 13G 1 d748776dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 0)*

     

     

    Prestige Consumer Healthcare Inc

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    74112D101

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 74112D101

     

     1.   

     Names of Reporting Persons

     

     Macquarie Group Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Sydney, New South Wales Australia

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,062,581 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust whose individual holdings are shown on the following forms.

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.17%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 2 of 13


    CUSIP No. 74112D101

     

     1.   

     Names of Reporting Persons

     

     Macquarie Management Holdings Inc

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     3,062,581

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     3,062,581

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,062,581 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.17%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 3 of 13


    CUSIP No. 74112D101

     

     1.   

     Names of Reporting Persons

     

     Macquarie Investment Management Business Trust

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     3,062,581

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     3,062,581

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,062,581

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.17%

    12.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    Page 4 of 13


    Item 1.

      

    (a)

      

    Name of Issuer

     

    Prestige Consumer Healthcare Inc

      

    (b)

      

    Address of Issuer’s Principal Executive Offices

     

    660 White Plains Road, Tarrytown, NY 10591

    Item 2.

       (a)   

    Name of Person Filing

     

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc and Macquarie Investment Management Business Trust

       (b)   

    Address of Principal Business Office or, if none, Residence

     

    The principal business address of Macquarie Group Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 610 Market Street, Philadelphia, PA 19106.

       (c)   

    Citizenship

     

    Macquarie Group Limited - Sydney, New South Wales, Australia Corporation

    Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust– incorporated or formed under the laws of the State of Delaware.

       (d)   

    Title of Class of Securities

     

    Common Stock

       (e)   

    CUSIP Number

     

    74112D101

    Item 3.

      

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 5 of 13


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)   

    Amount beneficially owned:

     

    See responses on the cover page hereto.

       (b)   

    Percent of class:

     

    See responses on the cover page hereto.

       (c)    Number of shares as to which the person has:
          (i)   

    Sole power to vote or to direct the vote

     

    See responses on the cover page hereto.

          (ii)   

    Shared power to vote or to direct the vote

     

    0

          (iii)   

    Sole power to dispose or to direct the disposition of

     

    See responses on the cover page hereto.

          (iv)   

    Shared power to dispose or to direct the disposition of

     

    0

    Item 5.    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See Exhibit A.
    Item 8.    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.    Notice of Dissolution of Group
    Not applicable.

     

    Page 6 of 13


    Item 10.

      

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited       February 14, 2024
          Date
    /s/ Philip Alexander       /s/ Charles Glorioso
    Signature       Signature
             

    Philip Alexander

    Associate Director

         

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.       February 14, 2024
          Date
    /s/ Marty Wolin      
    Signature      
           

    Marty Wolin

    Chief Compliance Officer

         

     

    Macquarie Investment Management Business Trust       February 14, 2024
          Date
    /s/ Marty Wolin      
    Signature      
           

    Marty Wolin

    Chief Compliance Officer

         

     

    Page 7 of 13

    Get the next $PBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    9/24/2025$80.00Neutral → Buy
    Sidoti
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    More analyst ratings

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

    TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer H

    9/4/25 7:00:03 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer downgraded by Sidoti with a new price target

    Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

    12/9/24 9:05:37 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by DA Davidson with a new price target

    DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

    6/21/24 7:05:28 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    8/13/25 4:14:05 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Prestige Consumer Healthcare Inc.

    10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:15:06 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:07:11 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kelly John F. was granted 2,094 shares, increasing direct ownership by 76% to 4,851 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:05:36 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zier Dawn M. was granted 2,094 shares, increasing direct ownership by 15% to 16,533 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:04:46 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hopkins Sheila was granted 2,094 shares, increasing direct ownership by 7% to 30,123 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:03:43 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 10:11:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/24 5:12:15 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    View All

    Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

    Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

    2/10/22 3:58:00 PM ET
    $LEAF
    $PBH
    $SPTN
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Financials

    Live finance-specific insights

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results

    TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes

    7/15/25 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care